Anavex Life Sciences Corp (AVXL)

[sokol]

I agree. Anavex has some form of exclusivity for AVXL 2-73 for AD alone not to mention the exclusivity it may have for all of the other uses. It certainly has 5-7 years FDA exclusivity in the U.S. if efficacy is proven for the treatment of AD and FDA approval is granted. It may also wind up with 20 years from the date of filing (maybe more with patent extensions) patent protection because of the application it has on file in the U.S. relative to AVXL 2-73 as a monotherapy for AD, which may be revived at any time. I addition, more patent protection may be granted (possibly very soon) for AVXL 2-73 combination AD treatment. Remember too that Anavex allegedly has some foreign patent protection for AVXL alone including, but not limited to, that once controversial Greek patent assigned to Anavex.

Anavex has competent patent counsel. I believe more patent protection will be forthcoming.

I disagree with anyone that thinks that a major pharmaceutical company would not be interested in AVXL 2-73 for the treatment of AD. If efficacy is proven, anyway you look at it Anavex has some exclusivity and a valuable drug. With efficacy, companies will be interested